Roberto Iacovelli

Faculty Profile Webpagehttps://docenti.unicatt.it/ppd2/linkPpdDocente?cod_docente=73799

Research activity per year

Academic discipline

MEDS-09/A - Medical Oncology

Fingerprint

Dive into the research topics where Roberto Iacovelli is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study
Iacovelli, R., Ciccarese, C., Buti, S., Zucali, P. A., Fantinel, E., Bimbatti, D., Verzoni, E., Accettura, C., Bonomi, L., Buttigliero, C., Fornarini, G., Pipitone, S., Atzori, F., Masini, C., Massari, F., Primi, F., Strusi, A., Giudice, G. C., Perrino, M. & Maruzzo, M. & 5 others, Milella, M., Giannarelli, D., Brunelli, M., Procopio, G. & Tortora, G., 2024, In: European Urology. 86, 5, p. 411-419 9 p.
Research output: Contribution to journal › Article
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Peltola, K., De, V. G., Burotto, M., Suarez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., Gumus, M., Stadler, W. M., Kollmannsberger, C., Melichar, B., Venugopal, B., Gross-Goupil, M., Poprach, A., De, S. M., Schutz, F. A. & Park, S. H. & 13 others, Nosov, D. A., Porta, C., Lee, J. L., Garcia-Del-Muro, X., Biscaldi, E., Manneh, K. R., Oya, M., He, L., Wang, A., Perini, R. F., Vickery, D., Albiges, L. & Rini, B., 2024, In: THE NEW ENGLAND JOURNAL OF MEDICINE. 391, 8, p. 710-721 12 p.
Research output: Contribution to journal › Article
Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy
Russo, P., Palermo, G., Iacovelli, R., Ragonese, M., Ciccarese, C., Maioriello, G., Fantasia, F., Bizzarri, F. P., Marino, F., Moosavi, K., Nigro, D., Filomena, G. B., Gavi, F., Rossi, F., Pinto, F., Racioppi, M. & Foschi, N., 2024, In: Cancers. 16, 3, p. N/A-N/A
Research output: Contribution to journal › Article
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Massari, F., Santoni, M., Takeshita, H., Okada, Y., Tapia, J. C., Basso, U., Maruzzo, M., Scagliarini, S., Büttner, T., Fornarini, G., Myint, Z. W., Galli, L., Souza, V. C., Pichler, R., De Giorgi, U., Gandur, N., Lam, E. T., Gilbert, D., Popovic, L. & Grande, E. & 77 others, Mammone, G., Berardi, R., Crabb, S. J., Kemp, R., Molina-Cerrillo, J., Freitas, M., Luz, M., Iacovelli, R., Calabrò, F., Tural, D., Atzori, F., Küronya, Z., Chiari, R., Campos, S., Caffo, O., Fay, A. P., Kucharz, J., Zucali, P. A., Rinck, J. A., Zeppellini, A., Bastos, D. A., Aurilio, G., Mota, A., Trindade, K., Ortega, C., Sade, J. P., Rizzo, M., Fiala, O., Vau, N., Giannatempo, P., Barillas, A., Monteiro, F. S. M., Dauster, B., Mennitto, A., Nogueira, L., De Carvalho Fernandes, R., Seront, E., Aceituno, L. G., Grillone, F., Cutuli, H. J., Fernandez, M., Bassanelli, M., Kopp, R. M., Roviello, G., Abahssain, H., Procopio, G., Milella, M., Kopecky, J., Martignetti, A., Messina, C., Caitano, M., Inman, E., Kanesvaran, R., Herchhorn, D., Santini, D., Bamias, A., Bisonni, R., Mosca, A., Morelli, F., Maluf, F., Soares, A., Nunes, F., Pinto, A., Zgura, A., Incorvaia, L., Ansari, J., Zabalza, I. O., Landmesser, J., Rizzo, A., Mollica, V., Marchetti, A., Rosellini, M., Sorgentoni, G., Battelli, N., Buti, S., Porta, C. & Bellmunt, J., 2024, In: Cancer Immunology, Immunotherapy. 73, p. 1-13 13 p.
Research output: Contribution to journal › Article
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni, M., Buti, S., Myint, Z. W., Maruzzo, M., Iacovelli, R., Pichler, M., Kopecky, J., Kucharz, J., Rizzo, M., Galli, L., Büttner, T., De Giorgi, U., Kanesvaran, R., Fiala, O., Grande, E., Zucali, P. A., Kopp, R. M., Fornarini, G., Bourlon, M. T. & Scagliarini, S. & 46 others, Molina-Cerrillo, J., Aurilio, G., Matrana, M. R., Pichler, R., Cattrini, C., Büchler, T., Massari, F., Seront, E., Calabrò, F., Pinto, A., Berardi, R., Zgura, A., Mammone, G., Ansari, J., Atzori, F., Chiari, R., Bamias, A., Caffo, O., Procopio, G., Sunela, K., Bassanelli, M., Ortega, C., Grillone, F., Landmesser, J., Milella, M., Messina, C., Küronya, Z., Mosca, A., Bhuva, D., Santini, D., Vau, N., Morelli, F., Incorvaia, L., Rebuzzi, S. E., Roviello, G., Soares, A., Bisonni, R., Bimbatti, D., Zabalza, I. O., Rizzo, A., Mollica, V., Sorgentoni, G., Monteiro, F. S. M., Battelli, N., Bracarda, S. & Porta, C., 2024, In: European urology oncology. 7, p. 102-111 10 p.
Research output: Contribution to journal › Article

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis
Ciccarese, C. (Creator), Anghelone, A. (Creator), Stefani, A. (Creator), Cigliola, A. (Creator), Strusi, A. (Creator), Bria, E. (Creator), Iacovelli, R. (Creator) & Tortora, G. (Creator), Taylor & Francis, 2024
DOI: 10.6084/m9.figshare.26046130, https://tandf.figshare.com/articles/dataset/The_incidence_and_relative_risk_of_major_adverse_cardiovascular_events_and_hypertension_in_patients_treated_with_immune_checkpoint_inhibitors_plus_tyrosine-kinase_inhibitors_for_solid_tumors_a_systemic_review_and_meta-analysis/26046130
Dataset
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis
Ciccarese, C. (Creator), Anghelone, A. (Creator), Stefani, A. (Creator), Cigliola, A. (Creator), Strusi, A. (Creator), Bria, E. (Creator), Iacovelli, R. (Creator) & Tortora, G. (Creator), Taylor & Francis, 2024
DOI: 10.6084/m9.figshare.26046130.v1, https://tandf.figshare.com/articles/dataset/The_incidence_and_relative_risk_of_major_adverse_cardiovascular_events_and_hypertension_in_patients_treated_with_immune_checkpoint_inhibitors_plus_tyrosine-kinase_inhibitors_for_solid_tumors_a_systemic_review_and_meta-analysis/26046130/1
Dataset

Roberto Iacovelli

Personal profile

Academic discipline

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

Roberto Iacovelli

Personal profile

Academic discipline

Fingerprint

Collaborations and top research areas from the last five years

Research output

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Datasets

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis